Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.

[1]  P. G. Choe,et al.  The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  A. McLachlan,et al.  Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring , 2012, Antimicrobial Agents and Chemotherapy.

[3]  J. Pilewski,et al.  Prospective, Observational Study of Voriconazole Therapeutic Drug Monitoring among Lung Transplant Recipients Receiving Prophylaxis: Factors Impacting Levels of and Associations between Serum Troughs, Efficacy, and Toxicity , 2012, Antimicrobial Agents and Chemotherapy.

[4]  R. Bies,et al.  Bioavailability and Population Pharmacokinetics of Voriconazole in Lung Transplant Recipients , 2010, Antimicrobial Agents and Chemotherapy.

[5]  F. Grenouillet,et al.  International Retrospective Analysis of 73 Cases of Invasive Fusariosis Treated with Voriconazole , 2010, Antimicrobial Agents and Chemotherapy.

[6]  Kazuaki Matsumoto,et al.  Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. , 2009, International journal of antimicrobial agents.

[7]  H. Klinker,et al.  Simultaneous Determination of Voriconazole and Posaconazole Concentrations in Human Plasma by High-Performance Liquid Chromatography , 2009, Antimicrobial Agents and Chemotherapy.

[8]  W. Haefeli,et al.  CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole , 2009, Journal of clinical pharmacology.

[9]  J. Donnelly,et al.  Therapeutic Drug Monitoring of Voriconazole , 2008, Therapeutic drug monitoring.

[10]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  N. Wood,et al.  Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities , 2006, Journal of clinical pharmacology.

[12]  B. Keevil,et al.  Adverse reactions to voriconazole. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  D. Andes,et al.  In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[14]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.

[15]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .